Delivery Order SPE2DB20D1100-SPE2DB25FC0C4

Award Date 4/29/25
Potential Completion Date 4/30/25
Potential Value $41K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of Cosentyx Unoready 300 mg Pen 2 mL. The order has a firm fixed price of $3,043.90 and is set to be completed by October 10, 2024. This contract is likely part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Cosentyx Unoready 300 mg pens, a prescription medication, with a ceiling value of $5,925.55 and a period of performance through April 2025. The contract is not set aside and is a firm fixed-price delivery order. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the procurement of Cosentyx Unoready 300 mg pens, a specialty medication, with a ceiling value of $3,149.12 and a period of performance through February 14, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation indicated. AmerisourceBergen holds a significant...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Cosentyx Unoready 300 mg pen, a medication used to treat certain medical conditions. The contract has a ceiling value of $3,333.86 and a period of performance through April 30, 2025. This order is not designated as a set-aside and is considered an open competition contract....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Cosentyx Unoready 300 mg pen injectors. The firm-fixed-price contract has a ceiling value of $27,745.00 and a performance period through August 27, 2024. It was awarded on August 26, 2024 and is not designated as a set-aside. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,525.01 firm fixed-price contract is for the delivery of Cosentyx Unoready 300 mg pen injectors. The award is associated with a $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of the pharmaceutical product Cosentyx Unoready 300 mg pen. The contract has a ceiling value of $1,521.95 and a completion date of May 9, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. Under this...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a wholly-owned subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is for the delivery of Cosentyx UNOREADY 300 mg pens, a specialty medication. The delivery order has a ceiling value of $1,521.95 and a period of performance through April 8, 2024. This award is associated...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of COSENTYX UNOREADY 300 MG PEN 2ML. The contract has a Firm Fixed Price pricing type and a total ceiling value of $4,828.04. The period of performance extends through January 16, 2025. This Delivery Order contract is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of COSENTYX UNOREADY 300 MG PEN 2ML, a pharmaceutical product, with a ceiling value of $6,717.96 and a performance period ending on April 18, 2025. The contract is a firm fixed-price, non-set-aside award. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB25FC0C4
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Cosentyx Unoready 300 mg pen 2 ml. The contract has a ceiling value of $41,001.50 and is a firm fixed-price delivery order, with a period of performance through April 30, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle for military healthcare programs through December 2026. The contract is not set aside and is open to full and open competition.

Generated 7/29/25, 9:55 AM